# venBio Partners

> venBio Partners is a VC fund backing Biotechnology and Health Care. See 98 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 98
- Last investment: Jun 2026
- Lead investor: 42%
- Fund size: $550M
- Last fund: May 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/venbio-partners/
- Website: http://venbio.com

venBio Partners is a VC fund in San Francisco focused on Biotechnology and Health Care. venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet theirrequirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.

## Contacts

5 contacts available for venBio Partners. Shizune tracks 4 team members at venBio Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/venbio?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $20M–$81M |
| Series B | $39M–$190M |
| Series C | $36M–$259M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 53 | 54% |
| Health Care | 32 | 33% |
| Pharmaceutical | 25 | 26% |
| Therapeutics | 22 | 22% |
| Medical | 17 | 17% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 27 | 28% |
| Series B | 23 | 23% |
| Series C | 16 | 16% |
| Post-IPO Equity | 7 | 7% |
| Series D | 6 | 6% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 48 | 49% |
| Canada | 4 | 4% |
| Switzerland | 2 | 2% |
| United Kingdom | 2 | 2% |
| China | 1 | 1% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Behzad Aghazadeh | Managing Team | 3 | https://shizune.co/investors/profile/behzad-aghazadeh |
| Corey Goodman | Managing Partner | 20 | https://shizune.co/investors/profile/corey-goodman |
| Richard Gaster | Managing Partner | 17 | https://shizune.co/investors/profile/richard-gaster |
| Robert Adelman | Managing Partner | 3 | https://shizune.co/investors/profile/robert-adelman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Oak hill bio | Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M | Series A | Jun 01, 2026 |  |
| Achieve Life Science | Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M | Post-IPO Equity | Apr 16, 2026 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $505M |  | Mar 02, 2026 |  |
| ALX Oncology | ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M | Post-IPO Equity | Jan 30, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| Yarrow | Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease. | $200M | Venture - Series Unknown | Dec 17, 2025 |  |
| Aeovian Pharmaceuticals | Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression,such as oxidative, cellular and environmental stress.Aeovian Pharmaceuticals was founded in 2012. | $55M | Series B | Dec 16, 2025 |  |
| LEXEO Therapeutics | LEXEO Therapeutics is a fully integrated biotechnology company. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. Beyond LEXEO Therapeutics’ lead programs – which are focused on both rare and non-rare monogenic (singlegenemutation) diseases – the company’s preclinical pipeline spans monogenic diseases, as well as hereditary and acquired diseases across a spectrum of patient population sizes and a range of unmet medical needs. Importantly, LEXEO Therapeutics will focus on advancing clinical programs through to commercialization, with the goal of maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to help advance the company’s pre-clinical pipeline. | $40M | Post-IPO Equity | Jun 24, 2025 |  |
| Attovia Therapeutics | Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated. | $90M | Series C | Apr 15, 2025 |  |
| Caldera Therapeutics | Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits.Caldera Therapeutics is a biotech company engaged in the development ofbispecific antibody CLD-423 for inflammatory bowel disease (IBD). | $75M | Series A | Apr 01, 2025 |  |

10 of 98 investments shown.

## Co-investors
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 26 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 16 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 16 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 16 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 15 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 15 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does venBio Partners invest in?

venBio Partners invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 98 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is venBio Partners's check size?

venBio Partners typically joins rounds of $20M–$81M at Series A, $39M–$190M at Series B and $36M–$259M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds venBio Partners participates in.

### How do I contact venBio Partners?

Public channels for venBio Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at venBio Partners?

The team at venBio Partners includes Behzad Aghazadeh (Managing Team), Corey Goodman (Managing Partner) and Richard Gaster (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co